Pet food company Freshpet (NASDAQ:FRPT) reported Q1 CY2025 results topping the market’s revenue expectations , with sales up 17.6% year on year to $263.2 million. On the other hand, the company’s full-year revenue guidance of $1.14 billion at the midpoint came in 3.2% below analysts’ estimates. Its GAAP loss of $0.26 per share was significantly below analysts’ consensus estimates. Is now the time to buy Freshpet? Find out in our full research report. Freshpet (FRPT) Q1 CY2025 Highlights: Revenue: $263.2 million vs analyst estimates of $259.6 million (17.6% year-on-year growth, 1.4% beat) EPS (GAAP): -$0.26 vs analyst estimates of $0.06 (significant miss) Adjusted EBITDA: $35.53 million vs analyst estimates of $34.14 million (13.5% margin, 4.1% beat) The company dropped its revenue guidance for the full year to $1.14 billion at the midpoint from $1.20 billion, a 5% decrease EBITDA guidance for the full year is $200 million at the midpoint, below analyst estimates of $205.1 million Operating Margin: -4.4%, down from 3.8% in the same quarter last year Free Cash Flow was -$21.68 million compared to -$41.07 million in the same quarter last year Organic Revenue was up 17.6% year on year Sales Volumes rose 14.9% year on year (30.6% in the same quarter last year) Market Capitalization: $3.72 billion “Despite the recent macro-economic headwinds, we believe Freshpet remains a structurally advantaged business with a long runway for growth in a category with long-term tailwinds. However, our growth year-to-date has not been as robust as we had anticipated so we are adapting our growth plans to the current economic challenges that our consumers are facing while continuing to drive the operational improvements that are essential to our long-term success,” commented Billy Cyr, Freshpet’s Chief Executive Officer. Company Overview Standing out from typical processed pet foods, Freshpet (NASDAQ:FRPT) is a pet food company whose product portfolio includes natural meals and treats for dogs and cats. Sales Growth A company’s long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. With $1.01 billion in revenue over the past 12 months, Freshpet is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers. On the bright side, it can grow faster because it has a longer list of untapped store chains to sell into. As you can see below, Freshpet’s sales grew at an exceptional 29.8% compounded annual growth rate over the last three years as consumers bought more of its products. Story Continues Freshpet Quarterly Revenue This quarter, Freshpet reported year-on-year revenue growth of 17.6%, and its $263.2 million of revenue exceeded Wall Street’s estimates by 1.4%. Looking ahead, sell-side analysts expect revenue to grow 21.3% over the next 12 months, a deceleration versus the last three years. Still, this projection is noteworthy and suggests the market is forecasting success for its products. Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Volume Growth Revenue growth can be broken down into changes in price and volume (the number of units sold). While both are important, volume is the lifeblood of a successful staples business as there’s a ceiling to what consumers will pay for everyday goods; they can always trade down to non-branded products if the branded versions are too expensive. Freshpet’s average quarterly volume growth of 24.1% over the last two years has beaten the competition by a long shot. This is great because companies with significant volume growth are needles in a haystack in the stable consumer staples sector.Freshpet Year-On-Year Volume Growth In Freshpet’s Q1 2025, sales volumes jumped 14.9% year on year. This result shows the business is staying on track, but the deceleration suggests growth is getting harder to come by. Key Takeaways from Freshpet’s Q1 Results We enjoyed seeing Freshpet beat analysts’ revenue and EBITDA expectations this quarter. On the other hand, its full-year revenue guidance missed significantly and its gross margin fell short of Wall Street’s estimates. Overall, this was a softer quarter. The stock traded down 3.5% to $73.70 immediately after reporting. The latest quarter from Freshpet’s wasn’t that good. One earnings report doesn’t define a company’s quality, though, so let’s explore whether the stock is a buy at the current price. When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it’s free. View Comments
Freshpet (NASDAQ:FRPT) Exceeds Q1 Expectations But Full-Year Sales Guidance Misses Expectations Significantly
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...